Mansfield Lyndon E, Mendoza Catherine P
El Paso Institute for Medical Research and Development, Tex 79902, USA.
South Med J. 2002 Mar;95(3):334-40.
A 12-month controlled pediatric study of intranasal beclomethasone dipropionate (BDP) reported a 0.9 cm decrease in annual height growth velocity. Since children with allergic rhinitis may be treated for years, this report evaluates long-term height growth effects.
We reviewed the clinical charts of children with allergic rhinitis who were treated for the first time with intranasal BDP and were less than 10 years of age at initiation. Height was determined by stadiometry before intranasal corticosteroid therapy and compared with height at a final visit.
Sixty children aged 24 to 117 months (mean age, 70 months) were treated for an average of 36 months. The pretherapy height percentile was 44.6, which increased to the 52.2 percentile at the final visit.
Long-term clinical use of intranasal BDP in children was not associated with decreased height growth. This outcome may reflect decreased long-term compliance compared with a short-term study. However, the treatment remained effective. Some children may be at special risk. Careful height measurements are recommended every 6 months.
一项为期12个月的关于丙酸倍氯米松鼻喷雾剂（BDP）的儿科对照研究报告称，年身高增长速度下降了0.9厘米。由于变应性鼻炎患儿可能需要接受数年治疗，本报告评估长期身高增长影响。
我们回顾了首次接受鼻内BDP治疗且开始治疗时年龄小于10岁的变应性鼻炎患儿的临床病历。在鼻内皮质类固醇治疗前通过身高测量仪测定身高，并与最后一次就诊时的身高进行比较。
60名年龄在24至117个月（平均年龄70个月）的儿童平均接受了36个月的治疗。治疗前身高百分位数为44.6，在最后一次就诊时增至52.2百分位数。
儿童长期临床使用鼻内BDP与身高增长下降无关。这一结果可能反映出与短期研究相比长期依从性降低。然而，治疗仍然有效。一些儿童可能存在特殊风险。建议每6个月仔细测量身高。
